Incyte Q2 Portfolio Surge: $1.49B Revenue, Jakafi XR Launch Underway

Biotech investors and drug developers should take note: Incyte’s second quarter illustrates how a mature hematology franchise can be rejuvenated through formulation innovation and broad payer acceptance. With Jakafi sales reaching $817 million on robust prescription growth and the newly launched extended-release formulation already capturing early prescriber interest, the company is building a durable revenue base while pushing its non-Jakafi pipeline toward a $3-4 billion target by 2030. The read-through for biotech valuations is clear—lifecycle management and portfolio diversification can deliver multi-year growth even as legacy products mature.

The second-quarter 2026 earnings season delivered a powerful signal of broad-based economic resilience, as a cross-section of industrial, pharmaceutical, technology, and mining companies all reported results that exceeded expectations and prompted upward guidance revisions. The common threads across the otherwise disparate reports from Procore Technologies, Incyte, Fuchs, Kinross Gold, and NPK International were robust demand, expanding margins, and confident capital allocation strategies—suggesting that corporate America entered the back half of the year with considerable momentum.

“

Incyte raised its full-year total net sales outlook to between $5.13 billion and $5.26 billion, reinforcing its trajectory toward a target of $3-4 billion in non-Jakafi revenue by 2030.

Procore Technologies, the construction software leader, posted revenue of $375 million, a 15.8% year-over-year increase that topped the high end of its own guidance by 2.5%. Even more striking was the leap in profitability: non-GAAP operating margin surged 800 basis points to 21.5%, and the company achieved its first-ever GAAP operating profit. This milestone, accompanied by a 507% jump in free cash flow to $65 million, underscores how software firms are successfully pivoting from growth-at-all-costs to a model of scalable, profitable expansion. Procore’s announcement of plans to acquire DroneDeploy signals an aggressive push into AI-powered job-site analytics, placing it at the intersection of construction tech and artificial intelligence.

Incyte’s results illustrated the power of a diversified pharmaceutical portfolio. Second-quarter net product sales reached $1.49 billion, up 40% from a year earlier, boosted by a one-time $246 million non-cash benefit tied to a CMS resolution for OPZELURA. Even excluding that item, sales grew 17%, with every marketed product recording year-over-year gains. Jakafi, the company’s flagship myelofibrosis treatment, generated $817 million in the quarter on 9% prescription growth, and the newly launched extended-release version, Jakafi XR, began to build momentum with $10 million in initial sales. Incyte raised its full-year total net sales outlook to between $5.13 billion and $5.26 billion, reinforcing its trajectory toward a target of $3-4 billion in non-Jakafi revenue by 2030.

Germany’s Fuchs, a global supplier of lubricants and industrial specialties, delivered its highest first-half EBIT on record, with sales rising 11% to €2 billion and EBIT jumping 24% to €260 million. The company disclosed that roughly one-third of its second-quarter growth came from customer pre-buying and another third from supply-driven share gains as competitors struggled with raw-material shortages—a dynamic that highlights both the staying power of industrial demand and the temporary tailwinds that may moderate in the second half. Nevertheless, Fuchs lifted its full-year EBIT guidance, citing strong volume growth across all regions.

In the commodities space, Kinross Gold produced 492,000 gold equivalent ounces in the quarter and generated $727 million in attributable free cash flow, bringing first-half free cash flow to more than $1.5 billion. With all-in sustaining costs of $1,821 per ounce and a realized margin of over $3,100 per ounce, the miner is returning capital at an aggressive pace: $275 million in share repurchases and dividends in Q2 alone, and a target of returning 40% of free cash flow to shareholders. The $2.7 billion cash position and net cash of $1.9 billion provide ample firepower for continued buybacks.